Side-by-side · Research reference
N-Acetyl Epitalon AmidatevsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED12/45 cited
BFDA-ApprovedHUMAN-REVIEWED13/41 cited
N-Acetyl Epitalon Amidate
Bioregulator Tetrapeptide · Khavinson School
SQ · Variable protocols
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
N-Acetyl Epitalon Amidate
PT-141
Primary target
DNA promoter regions (telomerase, RNA polymerase II, retinal genes)
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
Peptide → DNA complementary binding → Gene transcription initiation → Telomerase catalytic subunit expression
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Telomerase enzymatic activity induction, telomere elongation to early-passage length, extension of replicative lifespan in human somatic cellsKhavinson 2003Khavinson 2004
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
—
—
Origin
Synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from pineal extract bioregulator research; N-acetyl and C-amide modifications enhance plasma stability
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
N-Acetyl Epitalon Amidate
PT-141
Standard dose
No standardized human dosing in indexed literature
In vitro protocols use direct culture addition; human clinical dosing protocols are in Russian-language literature outside PubMed scope.
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Frequency
Not specified in candidate papers
PRN, max 8 doses / month
Evidence basis
In vitro human cell cultureKhavinson 2004Khavinson 2003
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Cell culture protocol
Addition to human fetal fibroblast culture induced telomerase activity and telomere elongation to early-passage lengthKhavinson 2004
Cells made 10 extra divisions (44 passages total vs 34 in control).
—
Duration
Chronic treatment in aging culture
Sustained effect through late passages.
PRN; reassess if no benefit after 8 doses
Modification stability
N-acetyl + C-amide caps enhance peptidase resistance
Standard strategy for tetrapeptide stabilization; specifics not quantified in candidates.
—
Lower / starter dose
—
1 mg (off-label)
Reconstitution
—
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Timing
—
≥45 min before sexual activity
04Side Effects & Safety
Parameter
N-Acetyl Epitalon Amidate
PT-141
Human safety data
Not available in indexed literature
Candidate papers describe in vitro and animal models only.
—
Theoretical telomerase risk
Telomerase activation in somatic cells raises theoretical oncogenic transformation concern
—
Flushing
—
Common, transient
Injection site reaction
—
Erythema, mild pain
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Pregnancy / OB
—
Contraindicated
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
N-Acetyl Epitalon Amidate
- ·Active malignancy or history of cancer — telomerase reactivation may promote tumor cell immortalization
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
N-Acetyl Epitalon Amidate
- ·Individuals with hereditary cancer syndromes or high genetic cancer risk
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
N-Acetyl Epitalon Amidate
PT-141
1. Route
Subcutaneous injection assumed based on peptide class; no specific protocol in candidate papers.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Reconstitution
Standard bacteriostatic water for lyophilized peptides. Exact volume not specified in indexed literature.
SQ — abdomen or thigh.
3. Storage
Lyophilized: -20 °C, desiccated. Reconstituted: refrigerate 2–8 °C. N-acetyl and C-amide modifications improve stability vs unprotected tetrapeptide.
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Clinical protocols
Human dosing schedules published in Russian-language clinical literature; not indexed in PubMed candidate set.
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Needle
—
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.
06Stack Synergy
N-Acetyl Epitalon Amidate
+ Thymalin
ModerateBoth are Khavinson-school bioregulators with epigenetic mechanisms. Thymalin targets thymic transcription factors for immune function, while Epitalon targets telomerase and pineal-axis genes. Combined use theoretically addresses dual axes of aging: replicative senescence and immune decline. Multi-target bioregulator strategy per Khavinson gerontology framework.
- Epitalon
- Protocol not defined in indexed literature
- Thymalin
- Tissue-specific bioregulator · separate dosing
- Rationale
- Complementary transcriptional targets
- Primary benefit
- Dual-axis aging intervention: cellular senescence + immune restoration
PT-141
— no documented stacks